TCL1A expression delineates biological and clinical variability in B-cell lymphoma
β Scribed by Aggarwal, Mohit; Villuendas, Raquel; Gomez, Gonzalo; Rodriguez-Pinilla, Socorro M; Sanchez-Beato, Margarita; Alvarez, David; Martinez, Nerea; Rodriguez, Antonia; Castillo, Maria E; Camacho, Francisca I; Montes-Moreno, Santiago; Garcia-Marco, Jose A; Kimby, Eva; Pisano, David G; Piris, Miguel A
- Book ID
- 118675791
- Publisher
- Nature Publishing Group
- Year
- 2008
- Tongue
- English
- Weight
- 751 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0893-3952
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. L
We investigated the expression of adhesion molecules of lymphocyte function-associated antigen-lu(LFAlu) and its ligand intercellular adhesion molecule-1 (ICAM-1) on 74 well-characterized B cell lymphomas. The LFA-1 was expressed on B cell lymphomas (2 1/74; 28 per cent), but to a lesser degree tha